SNY News | FINWIRES

European Equities Traded in US as ADRs Ease in Thursday Trading

European equities traded in the US as American depositary receipts eased late Thursday morning with the S&P Europe Select ADR Index dropping 0.1% to 1,801.52.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and pharmaceutical company Sanofi (SNY), which rose 6.4% and 2.5%, respectively. They were followed by biopharmaceutical company argenx (ARGX) and medical device maker EDAP TMS (EDAP), which were up 0.7% and 0.6%, respectively.The decliners from continental Europe were led by software firm SAP (SAP) and internet advertising company Criteo (CRTO), which fell 5% and 3.5%, respectively. They were followed by internet browser company Opera (OPRA) and 3D printer company Materialise (MTLS), which were down 3.2% and 3.1%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and hospitality company InterContinental Hotels Group (IHG), which advanced 4.8% and 2.4%, respectively. They were followed by biopharmaceutical company Amarin (AMRN) and telecommunications operator Vodafone Group (VOD), which increased 2% and 1.6%, respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Trinity Biotech (TRIB), which lost 6.4% and 6.2%, respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Akari Therapeutics (AKTX), which dropped 6.1% and 2.6%, respectively.

$AKTX$AMRN$ARGX$BDRX$CRTO$DAVA$EDAP$IHG$MTLS$NOK$OPRA$SAP$SLN$SNY$TRIB$VOD

Sector Update: Health Care Stocks Decline Premarket Thursday

Health care stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.7% lower.Thermo Fisher Scientific (TMO) stock was down more than 9% even after the company posted higher fiscal Q1 adjusted earnings and revenue.Sanofi (SNY) shares were up more than 3% after the company reported higher Q1 adjusted earnings and net sales.West Pharmaceutical Services (WST) stock was up more than 16% after the company reported higher Q1 non-GAAP earnings and net sales. West Pharmaceutical Services also issued Q2 outlook above analysts' expectations and raised its 2026 guidance.

$IBB$SNY$TMO$WST$XLV

Commodities53d ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Stalled US-Iran Talks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively traded Invesco QQQ Trust (QQQ) was 0.2% lower in Thursday's premarket activity as talks between the US and Iran stalled amid a continued blockage of the Strait of Hormuz.US stock futures were also lower, with S&P 500 Index futures down 0.4%, Dow Jones Industrial Average futures slipping 0.6%, and Nasdaq futures retreating 0.4% before the start of regular trading.US initial jobless claims totaled 214,000, compared with expectations of 210,000 and a prior reading of 208,000.The Chicago Federal Reserve Bank's monthly National Activity Index fell to a reading of minus 0.20 in March from 0.03 in February, compared with expectations for a smaller decrease to minus 0.13 in survey of analysts compiled by Bloomberg as of 7:35 am ET.S&P Global flash estimates of manufacturing and services conditions for April will be released at 9:45 am ET, followed by weekly natural gas stocks at 10:30 am ET.The Kansas City Fed's manufacturing reading for April will be released at 11 am ET.In premarket activity, bitcoin was down by 1.6%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.7% lower, Ether ETF (EETH) retreated by 3.3%, and Bitcoin & Ether Market Cap Weight ETF (BETH) declined by 0.02%.Power Play:EnergyThe iShares US Energy ETF (IYE) gained 0.03%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.4%.Helix Energy Solutions (HLX) stock was up more than 8% before the opening bell after the company agreed to merge with Hornbeck Offshore Services in an all-stock deal to form an integrated offshore services company.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.04%, the Vanguard Health Care Index Fund (VHT) was down 0.3%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) declined by 1.2%.Sanofi (SNY) stock was up more than 3% premarket after the company reported higher Q1 adjusted earnings and sales.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% lower.KB Financial Group (KB) shares were up more than 2% pre-bell after the company reported higher Q1 earnings and revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.04%, while the Vanguard Industrials Index Fund (VIS) gained 0.7% and the iShares US Industrials ETF (IYJ) was down 0.4%.Union Pacific (UNP) stock was up more than 2% before the opening bell after the company reported Q1 earnings and operating revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.3%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.5%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Tesla (TSLA) shares were down more than 2% pre-bell after the company overnight reported Q1 results, with investors focused on its outsized capital expenditure outlook.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.4%, and the iShares US Technology ETF (IYW) was flat, while the iShares Expanded Tech Sector ETF (IGM) was down 0.9%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 0.04% higher, while the iShares Semiconductor ETF (SOXX) rose by 0.9%.Intel (INTC) shares were up more than 1% in Thursday's premarket activity after Tesla (TSLA) Chief Executive Elon Musk said he intends to use Intel's upcoming 14A process to make chips at its Terafab advanced artificial intelligence project in Austin, Texas.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 0.2% to $93.17 per barrel on the New York Mercantile Exchange. Natural gas gained by 0.1% to reach $2.73 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.1%, while the United States Natural Gas Fund (UNG) was 0.4% lower.Gold futures for May were down by 0.4% at $4,734.40 an ounce on the Comex. Silver futures retreated by 3.1% to $76.11 an ounce. SPDR Gold Shares (GLD) was 0.3% lower, and the iShares Silver Trust (SLV) fell by 1.8%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$HLX$IBB$IGM$IGV$INTC$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$KB$PMR$QQQ$RTH$SLV$SNY$SOXX$SPY$TSLA$UNG$UNP$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD

Research Alert: Dupixent And Newer Drugs Power Sanofi Q1 Beat; Focus Turns To Incoming Ceo

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Sanofi's Q1 2026 results beat consensus, with sales of EUR10.5B (vs. the EUR10.3B consensus) growing 6.2% Y/Y or 13.6% at CER, while its business EPS of EUR1.88 beat the EUR1.80 consensus. Dupixent continued its strong trajectory with 30.8% CER growth, while new launches like Altuviiio grew 42.2% CER on patient switches from older treatments. Sanofi reiterated its 2026 guidance for high-single-digit sales growth at CER and business EPS growth slightly faster than sales, in line with consensus. We expect Dupixent and newer drugs to support the 2026 outlook. We continue to like Dupixent's strong growth and rising contribution from new launches, which should gradually reduce its revenue concentration risk. With limited patent expiry exposure until Dupixent's 2031 cliff, we view the long-term setup as positive. However, we view that near-term sentiment will depend on incoming CEO Belen Garijo's R&D strategy to improve execution and restore confidence after recent disappointing pipeline readouts.

$SNY

BNP Paribas Downgrades Sanofi to Neutral From Outperform, Lowers Price Target to $50 From $59

Sanofi (SNY) has an average rating of overweight and mean price target of $54.32, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SNY

European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading

European equities traded in the US as American depositary receipts began the week little changed late Monday morning, edging 0.02% higher to 1,822.16 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and telecommunications company Nokia (NOK), which advanced 26% and 9.3%, respectively. They were followed by furniture maker Natuzzi (NTZ) and biotech firm Evaxion (EVAX), which climbed 7.1% and 3.4%, respectively.The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and brewing company Anheuser-Busch InBev (BUD), which dropped 3.3% and 1.2%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and lender Banco Santander (SAN), which were off 0.9% and 0.8%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Mereo BioPharma Group (MREO), which rose 7% and 4.8%, respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and Bicycle Therapeutics (BCYC), which increased 4.1% and 2.4%, respectively.The decliners from the UK and Ireland were led by biotech company Trinity Biotech (TRIB) and cruise line operator Carnival (CUK), which fell 4.7% and 3.3%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and lender Barclays (BCS), which were down 2.2% and 0.9%, respectively.

$BCS$BCYC$BDRX$BUD$CLLS$CUK$EVAX$MREO$NCNA$NOK$NTZ$SAN$SLN$SNY$TRIB$TRVG